Capromab pendetide

DB00089ApprovedWithdrawnProtein Based Therapies

Capromab pendetide is a monoclonal anti-prostate specific membrane antigen antibody used in imaging kits to target radioactive agents to malignant prostate tissue. Capromab is a Murine IgG1 monoclonal 7E11-C5.3 antibody that recognizes prostate specific membrane antigen (PSMA – also known as glutamate carboxypeptidase 2) from prostate cancer cells and normal prostate tissue.

Protein structure of Capromab pendetide
Mechanism
Curator reviewed
Primary indication
For diagnosis of prostate cancer and detection of intra-pelvic metastases.Curator reviewed · 1 structured indication
First approval
United States, 1996
Also known as
(111In)-Capromab pendetide · Indium (111In) capromab pendetide · Indium 111 Capromab Pendetide · Indium In 111 capromab pendetide
Code names
CYT-356 · Cytogen 356

Resolves to

Compound
UNIIBDO5072GRXCAS145464-28-4ChEMBLCHEMBL2108285
Clinical / RWD
RxNorm136300ATCV09IB04PharmGKBPA164745489
Targets
Q04609FOLH1P07288KLK3

What you can answer from here — as of July 17, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
402Drug interactionsStructured to mechanism, not free text
Sign in
2Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
1Marketed productAcross 1 country and 1 labeller
Sign in
1ATC codeIncluding every combination product, plus 16 drug categories
Sign in
10+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Capromab pendetide, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In